西太平洋地区帕金森病
该地区与欧美在遗传因素、环境暴露、运动障碍及非运动症状方面存在差异,疾病认知不足和治疗可及性不均构成挑战,需改善基础设施、临床治理、服务及协同培训研究。
要点
- 西太平洋地区人口长寿化是全球帕金森病患病率指数增长的主因。
- 该地区与欧美在LRRK2突变等遗传因素及环境暴露作用上存在差异。
- 该地区报告的运动障碍较少,非运动症状和共病特征有差异。
核心结论
- 西太平洋地区帕金森病与欧美存在遗传、环境及临床特征差异,认知不足和治疗可及性不均构成挑战,需改善基础设施、临床治理、服务及协同培训研究。
研究设计与样本
- 本文为综述,未报告系统检索范围与样本量。
主要发现
- 该地区与欧美在LRRK2突变或变异等遗传因素上存在差异。
- 环境暴露在该地区对帕金森病风险的调节作用可能不同。
- 该地区报告的运动障碍较少,非运动症状和共病特征存在差异。
临床怎么用
- 临床应关注西太平洋地区帕金森病在遗传、环境及症状特征上的地区差异。
- 需改善基础设施、临床治理和服务以应对认知不足与治疗可及性不均。
- 应加强协同培训和研究,并增加该地区在临床试验中的代表性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
1·8 billion people of diverse ethnicities and cultures live in the Western Pacific Region. The increasing longevity of populations in this region is a major contributor to the exponential increase in Parkinson's disease prevalence worldwide. Differences exist between Parkinson's disease in the Western Pacific Region and in Europe and North America that might provide important insights into our understanding of the disease and approaches to management. For example, some genetic factors (such as LRRK2 mutations or variants) differ, environmental exposures might play differential roles in modulating the risk of Parkinson's disease, and fewer dyskinesias are reported, with some differences in the profile of non-motor symptoms and comorbidities. Gaps in awareness of the disease and inequitable access to treatments pose challenges. Further improvements in infrastructure, clinical governance, and services, and concerted collaborative efforts in training and research, including greater representation of the Western Pacific Region in clinical trials, will improve care of patients with Parkinson's disease in this region and beyond.
引用
- Lim SY, Tan AH, Ahmad-Annuar A, et al. Parkinson's disease in the Western Pacific Region. Lancet Neurol. 2019. PMID: 31175000. doi:10.1016/S1474-4422(19)30195-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。